GSK Changes Potiga Label In Response To Eye, Skin Issues

Law360, New York (April 29, 2013, 6:47 PM EDT) -- GlaxoSmithKline PLC said Monday it was in the process of changing the labeling for its anti-seizure drug Potiga, after the U.S. Food and Drug Administration warned the product may lead to vision problems and can cause users' skin to turn blue.

The FDA warned consumers Friday that use of Potiga, a drug developed by Valeant Pharmaceuticals International Inc. and distributed by GSK, can lead to discoloration of the lips, face, legs, fingernails and toenails. Potiga can also cause pigment changes to the retina, which can lead...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.